Targeting cardiac fibroblasts to treat fibrosis of the heart: Focus on HDACs

Journal of Molecular and Cellular Cardiology

Volumn 70, Issue , 2014, Pages 100-107

  Schuetze, Katherine B ^a   McKinsey, Timothy A ^a   Long, Carlin S ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Epigenetics; Fibroblast; Fibrosis; Histone acetylation

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANGIOTENSIN II; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE INHIBITOR; LYSINE; MITOGEN ACTIVATED PROTEIN KINASE; HISTONE;

ACETYLATION; CELL ACTIVATION; CELL ACTIVITY; CELL DIFFERENTIATION; CELL PROLIFERATION; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; FIBROBLAST; HEART MUSCLE FIBROSIS; HUMAN; MYOFIBROBLAST; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; ANIMAL; ARRHYTHMIAS, CARDIAC; DRUG EFFECTS; ENZYMOLOGY; FIBROSIS; GENE EXPRESSION REGULATION; GENETICS; HEART MUSCLE; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROTEIN PROCESSING; SIGNAL TRANSDUCTION;

ACETYLATION; ANIMALS; ARRHYTHMIAS, CARDIAC; FIBROSIS; GENE EXPRESSION REGULATION; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONES; HUMANS; LYSINE; MOLECULAR TARGETED THERAPY; MYOCARDIUM; MYOFIBROBLASTS; PROTEIN PROCESSING, POST-TRANSLATIONAL; SIGNAL TRANSDUCTION;

EID: 84899061619     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2014.02.015     Document Type: Review

References (133)

1. Richardson P., McKenna W., Bristow M., Maisch B., Mautner B., O'Connell J., et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation 1996, 93:841-842.
2. Maass A.H., Leinwand L.A. Mechanisms of the pathogenesis of troponin T-based familial hypertrophic cardiomyopathy. Trends Cardiovasc Med 2003, 13:232-237.
3. Brown R.D., Ambler S.K., Mitchell M.D., Long C.S. The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. Annu Rev Pharmacol Toxicol 2005, 45:657-687.
4. Virchow R. Die Cellularpathologie in ihrer Begrundung auf physiologische und pathologische Gewebelehre 1858, [Berlin].
5. Souders C.A., Bowers S.L., Baudino T.A. Cardiac fibroblast: the renaissance cell. Circ Res 2009, 105:1164-1176.
6. Sutherland A.E., Calarco P.G., Damsky C.H. Developmental regulation of integrin expression at the time of implantation in the mouse embryo. Development 1993, 119:1175-1186.
7. Zeisberg E.M., Tarnavski O., Zeisberg M., Dorfman A.L., McMullen J.R., Gustafsson E., et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med 2007, 13:952-961.
8. Malara A., Currao M., Gruppi C., Celesti G., Viarengo G., Buracchi C., Laghi L., Kaplan D.L., Balduini A. Megakaryocytes Contribute to the Bone Marrow-Matrix Environment by Expressing Fibronectin, Type IV Collagen, and Laminin. Stem Cells 2014 April, 32(4):926-937.
9. Merle B., Bouet G., Rousseau J.C., Bertholon C., Garnero P. Periostin and transforming growth factor beta-induced protein (TGFbetaIp) are both expressed by osteoblasts and osteoclasts. Cell Biol Int 2014 March, 38(3):398-404.
10. Puschmann T.B., Zanden C., Lebkuechner I., Philippot C., de P.Y., Liu J., Pekny M. HB-EGF affects astrocyte morphology, proliferation, differentiation, and the expression of intermediate filament proteins. J Neurochem 2014 March, 128(6):878-889.
11. Camelliti P., Borg T.K., Kohl P. Structural and functional characterisation of cardiac fibroblasts. Cardiovasc Res 2005, 65:40-51.
12. Goldsmith E.C., Hoffman A., Morales M.O., Potts J.D., Price R.L., McFadden A., et al. Organization of fibroblasts in the heart. Dev Dyn 2004, 230:787-794.
13. Simonneau L., Kitagawa M., Suzuki S., Thiery J.P. Cadherin 11 expression marks the mesenchymal phenotype: towards new functions for cadherins?. Cell Adhes Commun 1995, 3:115-130.
14. Valencia X., Higgins J.M., Kiener H.P., Lee D.M., Podrebarac T.A., Dascher C.C., et al. Cadherin-11 provides specific cellular adhesion between fibroblast-like synoviocytes. J Exp Med 2004, 200:1673-1679.
15. Mazzucchelli L. Protein S100A4: too long overlooked by pathologists?. Am J Pathol 2002, 160:7-13.
16. Ding S., Walton K.L., Blue R.E., McNaughton K., Magness S.T., Lund P.K. Mucosal healing and fibrosis after acute or chronic inflammation in wild type FVB-N mice and C57BL6 procollagen alpha1(I)-promoter-GFP reporter mice. PLoS One 2012, 7:e42568.
17. Magness S.T., Bataller R., Yang L., Brenner D.A. A dual reporter gene transgenic mouse demonstrates heterogeneity in hepatic fibrogenic cell populations. Hepatology 2004, 40:1151-1159.
18. Higashiyama R., Moro T., Nakao S., Mikami K., Fukumitsu H., Ueda Y., et al. Negligible contribution of bone marrow-derived cells to collagen production during hepatic fibrogenesis in mice. Gastroenterology 2009, 137:1459-1466.
19. Higashiyama R., Nakao S., Shibusawa Y., Ishikawa O., Moro T., Mikami K., et al. Differential contribution of dermal resident and bone marrow-derived cells to collagen production during wound healing and fibrogenesis in mice. J Invest Dermatol 2011, 131:529-536.
20. Barisic-Dujmovic T., Boban I., Clark S.H. Fibroblasts/myofibroblasts that participate in cutaneous wound healing are not derived from circulating progenitor cells. J Cell Physiol 2010, 222:703-712.
21. Chang H.Y., Chi J.T., Dudoit S., Bondre C., van de Rijn M., Botstein D., et al. Diversity, topographic differentiation, and positional memory in human fibroblasts. Proc Natl Acad Sci U S A 2002, 99:12877-12882.
22. Doane K.J., Birk D.E. Fibroblasts retain their tissue phenotype when grown in three-dimensional collagen gels. Exp Cell Res 1991, 195:432-442.
23. Brown R.D. Proinflammatory cytokines and cardiac extracellular matrix: regulation of fibroblast phenotype. Interstitial fibrosis in heart disease 2005, 57-81. Springer, New York. F.J. Villarreal (Ed.).
24. Driskell R.R., Lichtenberger B.M., Hoste E., Kretzschmar K., Simons B.D., Charalambous M., et al. Distinct fibroblast lineages determine dermal architecture in skin development and repair. Nature 2013, 504:277-281.
25. Beltrami A.P., Urbanek K., Kajstura J., Yan S.M., Finato N., Bussani R., et al. Evidence that human cardiac myocytes divide after myocardial infarction. N Engl J Med 2001, 344:1750-1757.
26. Camelliti P., Devlin G.P., Matthews K.G., Kohl P., Green C.R. Spatially and temporally distinct expression of fibroblast connexins after sheep ventricular infarction. Cardiovasc Res 2004, 62:415-425.
27. Porter K.E., Turner N.A. Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol Ther 2009, 123:255-278.
28. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev 1999, 79:215-262.
29. van Nieuwenhoven F.A., Turner N.A. The role of cardiac fibroblasts in the transition from inflammation to fibrosis following myocardial infarction. Vascul Pharmacol 2013, 58:182-188.
30. Wessels A., Perez-Pomares J.M. The epicardium and epicardially derived cells (EPDCs) as cardiac stem cells. Anat Rec A Discov Mol Cell Evol Biol 2004, 276:43-57.
31. Baum J., Duffy H.S. Fibroblasts and myofibroblasts: what are we talking about?. J Cardiovasc Pharmacol 2011, 57:376-379.
32. Tveito A., Lines G., Artebrant R., Skavhaug O., Maleckar M.M. Existence of excitation waves for a collection of cardiomyocytes electrically coupled to fibroblasts. Math Biosci 2011, 230:79-86.
33. Zeisberg M., Kalluri R. Cellular mechanisms of tissue fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis. Am J Physiol Cell Physiol 2013, 304:C216-C225.
34. Camelliti P., McCulloch A.D., Kohl P. Microstructured cocultures of cardiac myocytes and fibroblasts: a two-dimensional in vitro model of cardiac tissue. Microsc Microanal 2005, 11:249-259.
35. Camelliti P., Green C.R., LeGrice I., Kohl P. Fibroblast network in rabbit sinoatrial node: structural and functional identification of homogeneous and heterogeneous cell coupling. Circ Res 2004, 94:828-835.
36. Baudino T.A., Carver W., Giles W., Borg T.K. Cardiac fibroblasts: friend or foe?. Am J Physiol Heart Circ Physiol 2006, 291:H1015-H1026.
37. Darland D.C., D'Amore P.A. Cell-cell interactions in vascular development. Curr Top Dev Biol 2001, 52:107-149.
38. Davis G.E., Senger D.R. Endothelial extracellular matrix: biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circ Res 2005, 97:1093-1107.
39. Gaudesius G., Miragoli M., Thomas S.P., Rohr S. Coupling of cardiac electrical activity over extended distances by fibroblasts of cardiac origin. Circ Res 2003, 93:421-428.
40. Manabe I., Shindo T., Nagai R. Gene expression in fibroblasts and fibrosis: involvement in cardiac hypertrophy. Circ Res 2002, 91:1103-1113.
41. Sussman M.A., McCulloch A., Borg T.K. Dance band on the Titanic: biomechanical signaling in cardiac hypertrophy. Circ Res 2002, 91:888-898.
42. Singh V.P., Baker K.M., Kumar R. Activation of the intracellular renin-angiotensin system in cardiac fibroblasts by high glucose: role in extracellular matrix production. Am J Physiol Heart Circ Physiol 2008, 294:H1675-H1684.
43. Tomasek J.J., Gabbiani G., Hinz B., Chaponnier C., Brown R.A. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 2002, 3:349-363.
44. Petrov V.V., Fagard R.H., Lijnen P.J. Stimulation of collagen production by transforming growth factor-beta1 during differentiation of cardiac fibroblasts to myofibroblasts. Hypertension 2002, 39:258-263.
45. Valente A.J., Sakamuri S.S., Siddesha J.M., Yoshida T., Gardner J.D., Prabhu R., Siebenlist U., Chandrasekar B. TRAF3IP2 mediates interleukin-18-induced cardiac fibroblast migration and differentiation. Cell Signal 2013 November, 25(11):2176-2184.
46. Zhao T., Zhao W., Chen Y., Li V.S., Meng W., Sun Y. Platelet-derived growth factor-D promotes fibrogenesis of cardiac fibroblasts. Am J Physiol Heart Circ Physiol 2013, 304:H1719-H1726.
47. Adapala R.K., Thoppil R.J., Luther D.J., Paruchuri S., Meszaros J.G., Chilian W.M., et al. TRPV4 channels mediate cardiac fibroblast differentiation by integrating mechanical and soluble signals. J Mol Cell Cardiol 2013, 54:45-52.
48. Dalla Costa A.P., Clemente C.F., Carvalho H.F., Carvalheira J.B., Nadruz W., Franchini K.G. FAK mediates the activation of cardiac fibroblasts induced by mechanical stress through regulation of the mTOR complex. Cardiovasc Res 2010, 86:421-431.
49. Herum K.M., Lunde I.G., Skrbic B., Florholmen G., Behmen D., Sjaastad I., et al. Syndecan-4 signaling via NFAT regulates extracellular matrix production and cardiac myofibroblast differentiation in response to mechanical stress. J Mol Cell Cardiol 2013, 54:73-81.
50. Santiago J.J., Dangerfield A.L., Rattan S.G., Bathe K.L., Cunnington R.H., Raizman J.E., et al. Cardiac fibroblast to myofibroblast differentiation in vivo and in vitro: expression of focal adhesion components in neonatal and adult rat ventricular myofibroblasts. Dev Dyn 2010, 239:1573-1584.
51. Khouw I.M., van Wachem P.B., Plantinga J.A., Vujaskovic Z., Wissink M.J., de Leij L.F., et al. TGF-beta and bFGF affect the differentiation of proliferating porcine fibroblasts into myofibroblasts in vitro. Biomaterials 1999, 20:1815-1822.
52. Rohr S. Cardiac fibroblasts in cell culture systems: myofibroblasts all along?. J Cardiovasc Pharmacol 2011, 57:389-399.
53. Wang J., Chen H., Seth A., McCulloch C.A. Mechanical force regulation of myofibroblast differentiation in cardiac fibroblasts. Am J Physiol Heart Circ Physiol 2003, 285:H1871-H1881.
54. Turner N.A., Porter K.E. Function and fate of myofibroblasts after myocardial infarction. Fibrogenesis Tissue Repair 2013, 6:5.
55. Yue Z., Zhang Y., Xie J., Jiang J., Yue L. Transient receptor potential (TRP) channels and cardiac fibrosis. Curr Top Med Chem 2013, 13:270-282.
56. Gan Q., Yoshida T., Li J., Owens G.K. Smooth muscle cells and myofibroblasts use distinct transcriptional mechanisms for smooth muscle alpha-actin expression. Circ Res 2007, 101:883-892.
57. Frangogiannis N.G., Michael L.H., Entman M.L. Myofibroblasts in reperfused myocardial infarcts express the embryonic form of smooth muscle myosin heavy chain (SMemb). Cardiovasc Res 2000, 48:89-100.
58. Sun Y., Weber K.T. RAS and connective tissue in the heart. Int J Biochem Cell Biol 2003, 35:919-931.
59. Blankesteijn W.M., Essers-Janssen Y.P., Verluyten M.J., Daemen M.J., Smits J.F. A homologue of Drosophila tissue polarity gene frizzled is expressed in migrating myofibroblasts in the infarcted rat heart. Nat Med 1997, 3:541-544.
60. Weber K.T., Sun Y., Bhattacharya S.K., Ahokas R.A., Gerling I.C. Myofibroblast-mediated mechanisms of pathological remodelling of the heart. Nat Rev Cardiol 2013, 10:15-26.
61. Cleutjens J.P., Verluyten M.J., Smiths J.F., Daemen M.J. Collagen remodeling after myocardial infarction in the rat heart. Am J Pathol 1995, 147:325-338.
62. Filip D.A., Radu A., Simionescu M. Interstitial cells of the heart valves possess characteristics similar to smooth muscle cells. Circ Res 1986, 59:310-320.
63. van den Borne S.W., Diez J., Blankesteijn W.M., Verjans J., Hofstra L., Narula J. Myocardial remodeling after infarction: the role of myofibroblasts. Nat Rev Cardiol 2010, 7:30-37.
64. Willems I.E., Havenith M.G., De Mey J.G., Daemen M.J. The alpha-smooth muscle actin-positive cells in healing human myocardial scars. Am J Pathol 1994, 145:868-875.
65. Vasquez C., Morley G.E. The origin and arrhythmogenic potential of fibroblasts in cardiac disease. J Cardiovasc Transl Res 2012, 5:760-767.
66. Yano T., Miura T., Ikeda Y., Matsuda E., Saito K., Miki T., et al. Intracardiac fibroblasts, but not bone marrow derived cells, are the origin of myofibroblasts in myocardial infarct repair. Cardiovasc Pathol 2005, 14:241-246.
67. Carlson S., Trial J., Soeller C., Entman M.L. Cardiac mesenchymal stem cells contribute to scar formation after myocardial infarction. Cardiovasc Res 2011, 91:99-107.
68. Dubois C., Liu X., Claus P., Marsboom G., Pokreisz P., Vandenwijngaert S., et al. Differential effects of progenitor cell populations on left ventricular remodeling and myocardial neovascularization after myocardial infarction. J Am Coll Cardiol 2010, 55:2232-2243.
69. Potts J.D., Runyan R.B. Epithelial-mesenchymal cell transformation in the embryonic heart can be mediated, in part, by transforming growth factor beta. Dev Biol 1989, 134:392-401.
70. Norris R.A., Borg T.K., Butcher J.T., Baudino T.A., Banerjee I., Markwald R.R. Neonatal and adult cardiovascular pathophysiological remodeling and repair: developmental role of periostin. Ann N Y Acad Sci 2008, 1123:30-40.
71. Bucala R., Spiegel L.A., Chesney J., Hogan M., Cerami A. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med 1994, 1:71-81.
72. Haudek S.B., Xia Y., Huebener P., Lee J.M., Carlson S., Crawford J.R., et al. Bone marrow-derived fibroblast precursors mediate ischemic cardiomyopathy in mice. Proc Natl Acad Sci U S A 2006, 103:18284-18289.
73. Haudek S.B., Cheng J., Du J., Wang Y., Hermosillo-Rodriguez J., Trial J., et al. Monocytic fibroblast precursors mediate fibrosis in angiotensin-II-induced cardiac hypertrophy. J Mol Cell Cardiol 2010, 49:499-507.
74. Mollmann H., Nef H.M., Kostin S., von K.C., Pilz I., Weber M., et al. Bone marrow-derived cells contribute to infarct remodelling. Cardiovasc Res 2006, 71:661-671.
75. Odorfer K.I., Walter I., Kleiter M., Sandgren E.P., Erben R.G. Role of endogenous bone marrow cells in long-term repair mechanisms after myocardial infarction. J Cell Mol Med 2008, 12:2867-2874.
76. Sato D., Otani H., Enoki C., Fujita M., Minato N., Iwasaka T. Phenotypic modulation and turnover of bone marrow-derived cells after myocardial infarction in rats. Cardiovasc Pathol 2011, 20:146-155.
77. van Amerongen M.J., Bou-Gharios G., Popa E., van A.J., Petersen A.H., van Dam G.M., et al. Bone marrow-derived myofibroblasts contribute functionally to scar formation after myocardial infarction. J Pathol 2008, 214:377-386.
78. Piera-Velazquez S., Li Z., Jimenez S.A. Role of endothelial-mesenchymal transition (EndoMT) in the pathogenesis of fibrotic disorders. Am J Pathol 2011, 179:1074-1080.
79. Widyantoro B., Emoto N., Nakayama K., Anggrahini D.W., Adiarto S., Iwasa N., et al. Endothelial cell-derived endothelin-1 promotes cardiac fibrosis in diabetic hearts through stimulation of endothelial-to-mesenchymal transition. Circulation 2010, 121:2407-2418.
80. Strutz F., Okada H., Lo C.W., Danoff T., Carone R.L., Tomaszewski J.E., et al. Identification and characterization of a fibroblast marker: FSP1. J Cell Biol 1995, 130:393-405.
81. Ronnov-Jessen L., Petersen O.W., Koteliansky V.E., Bissell M.J. The origin of the myofibroblasts in breast cancer. Recapitulation of tumor environment in culture unravels diversity and implicates converted fibroblasts and recruited smooth muscle cells. J Clin Invest 1995, 95:859-873.
82. Gonzalez-Rosa J.M., Peralta M., Mercader N. Pan-epicardial lineage tracing reveals that epicardium derived cells give rise to myofibroblasts and perivascular cells during zebrafish heart regeneration. Dev Biol 2012, 370:173-186.
83. Di M.F., Castaldo C., Nurzynska D., Romano V., Miraglia R., Bancone C., et al. Epithelial-mesenchymal transition of epicardial mesothelium is a source of cardiac CD117-positive stem cells in adult human heart. J Mol Cell Cardiol 2010, 49:719-727.
84. Russell J.L., Goetsch S.C., Gaiano N.R., Hill J.A., Olson E.N., Schneider J.W. A dynamic notch injury response activates epicardium and contributes to fibrosis repair. Circ Res 2011, 108:51-59.
85. Smart N., Risebro C.A., Melville A.A., Moses K., Schwartz R.J., Chien K.R., et al. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature 2007, 445:177-182.
86. van T.J., Atsma D.E., Winter E.M., van der Velde-van Dijke, Pijnappels D.A., Bax N.A., et al. Epicardial cells of human adults can undergo an epithelial-to-mesenchymal transition and obtain characteristics of smooth muscle cells in vitro. Stem Cells 2007, 25:271-278.
87. Lin S.L., Kisseleva T., Brenner D.A., Duffield J.S. Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney. Am J Pathol 2008, 173:1617-1627.
88. Pichler M., Rainer P.P., Schauer S., Hoefler G. Cardiac fibrosis in human transplanted hearts is mainly driven by cells of intracardiac origin. J Am Coll Cardiol 2012, 59:1008-1016.
89. Wu G.D., Tuan T.L., Bowdish M.E., Jin Y.S., Starnes V.A., Cramer D.V., et al. Evidence for recipient derived fibroblast recruitment and activation during the development of chronic cardiac allograft rejection. Transplantation 2003, 76:609-614.
90. Sun Y., Zhang J.Q., Zhang J., Ramires F.J. Angiotensin II, transforming growth factor-beta1 and repair in the infarcted heart. J Mol Cell Cardiol 1998, 30:1559-1569.
91. Katwa L.C., Campbell S.E., Tyagi S.C., Lee S.J., Cicila G.T., Weber K.T. Cultured myofibroblasts generate angiotensin peptides de novo. J Mol Cell Cardiol 1997, 29:1375-1386.
92. Weber K.T., Sun Y., Campbell S.E. Structural remodelling of the heart by fibrous tissue: role of circulating hormones and locally produced peptides. Eur Heart J 1995, 16(Suppl. N):12-18.
93. Takeda Y., Zhu A., Yoneda T., Usukura M., Takata H., Yamagishi M. Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats. Am J Hypertens 2007, 20:1119-1124.
94. Zhao Y.X., Yin H.Q., Yu Q.T., Qiao Y., Dai H.Y., Zhang M.X., et al. ACE2 overexpression ameliorates left ventricular remodeling and dysfunction in a rat model of myocardial infarction. Hum Gene Ther 2010, 21:1545-1554.
95. Diez J., Querejeta R., Lopez B., Gonzalez A., Larman M., Martinez Ubago J.L. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 2002, 105:2512-2517.
96. Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009, 325:834-840.
97. Lundby A., Lage K., Weinert B.T., Bekker-Jensen D.B., Secher A., Skovgaard T., et al. Proteomic analysis of lysine acetylation sites in rat tissues reveals organ specificity and subcellular patterns. Cell Rep 2012, 2:419-431.
98. Gregoretti I.V., Lee Y.M., Goodson H.V. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 2004, 338:17-31.
99. Alcendor R.R., Gao S., Zhai P., Zablocki D., Holle E., Yu X., et al. Sirt1 regulates aging and resistance to oxidative stress in the heart. Circ Res 2007, 100:1512-1521.
100. Gallo P., Latronico M.V., Gallo P., Grimaldi S., Borgia F., Todaro M., et al. Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failure. Cardiovasc Res 2008, 80:416-424.
101. Kee H.J., Sohn I.S., Nam K.I., Park J.E., Qian Y.R., Yin Z., et al. Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding. Circulation 2006, 113:51-59.
102. Kong Y., Tannous P., Lu G., Berenji K., Rothermel B.A., Olson E.N., et al. Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy. Circulation 2006, 113:2579-2588.
103. Liu F., Levin M.D., Petrenko N.B., Lu M.M., Wang T., Yuan L.J., et al. Histone-deacetylase inhibition reverses atrial arrhythmia inducibility and fibrosis in cardiac hypertrophy independent of angiotensin. J Mol Cell Cardiol 2008, 45:715-723.
104. Goumans M.J., van Zonneveld A.J., ten D.P. Transforming growth factor beta-induced endothelial-to-mesenchymal transition: a switch to cardiac fibrosis?. Trends Cardiovasc Med 2008, 18:293-298.
105. Weiskirchen R., Meurer S.K., Gressner O.A., Herrmann J., Borkham-Kamphorst E., Gressner A.M. BMP-7 as antagonist of organ fibrosis. Front Biosci (Landmark Ed) 2009, 14:4992-5012.
106. Peinado H., Ballestar E., Esteller M., Cano A. Snail mediates E-cadherin repression by the recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex. Mol Cell Biol 2004, 24:306-319.
107. Barter M.J., Pybus L., Litherland G.J., Rowan A.D., Clark I.M., Edwards D.R., et al. HDAC-mediated control of ERK- and PI3K-dependent TGF-beta-induced extracellular matrix-regulating genes. Matrix Biol 2010, 29:602-612.
108. Liu N., He S., Ma L., Ponnusamy M., Tang J., Tolbert E., et al. Blocking the class I histone deacetylase ameliorates renal fibrosis and inhibits renal fibroblast activation via modulating TGF-beta and EGFR signaling. PLoS One 2013, 8:e54001.
109. Williams S.M., Golden-Mason L., Ferguson B.S., Schuetze K.B., Cavasin M.A., Demos-Davies K., Yeager M.E., Stenmark K.R., McKinsey T.A. Class I HDACs regulate angiotensin II-dependent cardiac fibrosis via fibroblasts and circulating fibrocytes. J Mol Cell Cardiol 2014 February, 67:112-125.
110. Boumber Y., Younes A., Garcia-Manero G. Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor. Expert Opin Investig Drugs 2011, 20:823-829.
111. Gui C.Y., Ngo L., Xu W.S., Richon V.M., Marks P.A. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci U S A 2004, 101:1241-1246.
112. Li H., Wu X. Histone deacetylase inhibitor, Trichostatin A, activates p21WAF1/CIP1 expression through downregulation of c-myc and release of the repression of c-myc from the promoter in human cervical cancer cells. Biochem Biophys Res Commun 2004, 324:860-867.
113. Marks P.A. The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin Investig Drugs 2010, 19:1049-1066.
114. Richon V.M., Sandhoff T.W., Rifkind R.A., Marks P.A. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A 2000, 97:10014-10019.
115. Sambucetti L.C., Fischer D.D., Zabludoff S., Kwon P.O., Chamberlin H., Trogani N., et al. Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J Biol Chem 1999, 274:34940-34947.
116. Fass D.M., Shah R., Ghosh B., Hennig K., Norton S., Zhao W.N., et al. Effect of inhibiting histone deacetylase with short-chain carboxylic acids and their hydroxamic acid analogs on vertebrate development and neuronal chromatin. ACS Med Chem Lett 2010, 2:39-42.
117. Cardinale J.P., Sriramula S., Pariaut R., Guggilam A., Mariappan N., Elks C.M., et al. HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive rats. Hypertension 2010, 56:437-444.
118. Iyer A., Fenning A., Lim J., Le G.T., Reid R.C., Halili M.A., et al. Antifibrotic activity of an inhibitor of histone deacetylases in DOCA-salt hypertensive rats. Br J Pharmacol 2010, 159:1408-1417.
119. Bradner J.E., West N., Grachan M.L., Greenberg E.F., Haggarty S.J., Warnow T., et al. Chemical phylogenetics of histone deacetylases. Nat Chem Biol 2010, 6:238-243.
120. Herzog E.L., Bucala R. Fibrocytes in health and disease. Exp Hematol 2010, 38:548-556.
121. Peng H., Herzog E.L. Fibrocytes: emerging effector cells in chronic inflammation. Curr Opin Pharmacol 2012, 12:491-496.
122. Reilkoff R.A., Bucala R., Herzog E.L. Fibrocytes: emerging effector cells in chronic inflammation. Nat Rev Immunol 2011, 11:427-435.
123. Cieslik K.A., Taffet G.E., Carlson S., Hermosillo J., Trial J., Entman M.L. Immune-inflammatory dysregulation modulates the incidence of progressive fibrosis and diastolic stiffness in the aging heart. J Mol Cell Cardiol 2011, 50:248-256.
124. Sopel M., Falkenham A., Oxner A., Ma I., Lee T.D., Legare J.F. Fibroblast progenitor cells are recruited into the myocardium prior to the development of myocardial fibrosis. Int J Exp Pathol 2012, 93:115-124.
125. Xu J., Lin S.C., Chen J., Miao Y., Taffet G.E., Entman M.L., et al. CCR2 mediates the uptake of bone marrow-derived fibroblast precursors in angiotensin II-induced cardiac fibrosis. Am J Physiol Heart Circ Physiol 2011, 301:H538-H547.
126. Keeley E.C., Mehrad B., Janardhanan R., Salerno M., Hunter J.R., Burdick M.M., et al. Elevated circulating fibrocyte levels in patients with hypertensive heart disease. J Hypertens 2012, 30:1856-1861.
127. Duffield J.S., Lupher M.L. PRM-151 (recombinant human serum amyloid P/pentraxin 2) for the treatment of fibrosis. Drug News Perspect 2010, 23:305-315.
128. Duerrschmid C., Crawford J.R., Reineke E., Taffet G.E., Trial J., Entman M.L., Haudek S.B. TNF receptor 1 signaling is critically involved in mediating angiotensin-II-induced cardiac fibrosis. J Mol Cell Cardiol 2013 April, 57:59-67.
129. Nikam V.S., Wecker G., Schermuly R., Rapp U., Szelepusa K., Seeger W., et al. Treprostinil inhibits the adhesion and differentiation of fibrocytes via the cyclic adenosine monophosphate-dependent and Ras-proximate protein-dependent inactivation of extracellular regulated kinase. Am J Respir Cell Mol Biol 2011, 45:692-703.
130. Haudek S.B., Gupta D., Dewald O., Schwartz R.J., Wei L., Trial J., et al. Rho kinase-1 mediates cardiac fibrosis by regulating fibroblast precursor cell differentiation. Cardiovasc Res 2009, 83:511-518.
131. Kokubo S., Sakai N., Furuichi K., Toyama T., Kitajima S., Okumura T., et al. Activation of p38 mitogen-activated protein kinase promotes peritoneal fibrosis by regulating fibrocytes. Perit Dial Int 2012, 32:10-19.
132. Shao D.D., Suresh R., Vakil V., Gomer R.H., Pilling D. Pivotal advance: Th-1 cytokines inhibit, and Th-2 cytokines promote fibrocyte differentiation. J Leukoc Biol 2008, 83:1323-1333.
133. Ferguson B.S., Harrison B.C., Jeong M.Y., Reid B.G., Wempe M.F., Wagner F.F., et al. Signal-dependent repression of DUSP5 by class I HDACs controls nuclear ERK activity and cardiomyocyte hypertrophy. Proc Natl Acad Sci U S A 2013, 110:9806-9811.